Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet; November 2019, Vol. 394 Issue: 10212 p1929-1939, 11p
- Subject
- Language
- ISSN
- 01406736; 1474547X